Long time off this platform.. excited to be back to share that I have been elected President of the @thesfpm.bsky.social alongside @boehmjesse.bsky.social. This community has been a true home for those of us for whom patient-derived models and functional testing belong at the center of cancer care/n

Great to hear Iain Foulkes join @break-cancer.bsky.social's @boehmjesse.bsky.social, @su2c.bsky.social's Julian Adams & NUT Carcinoma Alliance's Maddie Musselman at @milkeninstitute.org #MIHealthSummit to discuss how global collaboration can drive innovation in cancer research #CancerGrandChallenges

It was a great discussion! There has never before been so much opportunity to work together to solve the major challenges of our field.

We are very proud of our Accelerating GBM Therapies TeamLab for this outstanding, potentially field changing work. We must sample continuously to understand hidden, temporal responses to therapy. Even in the brain.

Excited to get this out there as we go through revisions. These findings have changed how I think about KIAA1549-BRAF of pediatric gliomas, and all other fusions, completely. The fusion partner is important, necessary and engenders novel vulnerabilities that can be therapeutically targeted.

Be sure to catch Jesse Boehm @boehmjesse.bsky.social in the Tumoroids, Organoids, and Cell Culture session at #AACR25! He’ll present how patient-derived cancer models are shaping research on rare and understudied cancers. 🔗 www.abstractsonline.com/pp8/#!/20273...

Today marks the beginning of OpenRxiv, which replaces bioRxiv and medRxiv, the world's largest preprint platform for life and medical science openrxiv.org/introducing-... @openrxiv.bsky.social

Research support for rare diseases, which cumulatively affect ~30 million Americans, is primarily derived from NIH. Such work is exemplified by Prof Anna Greka @broadinstitute.org in a new Ground Truths podcast. Open-access, w/ transcript, video, no ads erictopol.substack.com/p/anna-greka...

3 points of progress vs pancreatic cancer! 1. Neoantigen vaccines www.nature.com/articles/s41... 2. KRAS drugs www.wsj.com/health/healt... 3. Early diagnosis www.science.org/doi/10.1126/...

Francis Collins, the NIH Director for 12 years, led the Human Genome Project and other NIH efforts for 32 years, resigned today. Key words from his resignation letter www.nytimes.com/2025/03/01/u...

“The rare tumor space is an example of where we should think hard about the quality data that we have and how we can help inform future treatments,” @danafarber.bsky.social’s Suzanne George, MD, shared at #RareDiseaseSummit 2025.

Inexplicably, US administration has launched an unprecedented assault on science, on research institutions & on vital international organizations & initiatives. An assault on science anywhere is an assault on science everywhere; the global community must unite 🧪 www.nature.com/articles/d41...

Excited to be speaking this Tuesday, Feb. 25 at #RareDiseaseSummit 2025, @GlobeEvent’s inaugural summit focused on innovation and advocacy in rare disease, “From Bench to Bedside: Rare Cancer Innovations.” Sign up to join in person or virtually: @bostonglobe.com rarediseasesummit2025.splashthat.com

Exciting new synthetic lethal target emerging from #depmap data 🧪🧬 Frequent passenger mutations in genes involved in mRNA quality control lead to a dependency on PELO-HBS1L Congratulations to the DepMap team! @vazquezf.bsky.social #depmap #cancertarget #syntheticlethal

(1/3) Excited to share our latest work using @depmap.org to uncover a new synthetic lethality in two distinct patient populations! We found that SKI complex inactivation through two independent genomic alterations creates a dependency on PELO #CancerResearch #SyntheticLethality #Genomics #DepMap

A full attack on US science means the red & blue lines will soon cross. Scientists just want science to progress to help society. This administration - and "Pres Musk" - is telling us they don't need/want US science. We will see many of our great ideas and innovation will go to China and elsewhere

Breaking news: The Trump administration cut billions in biomedical funding. Researchers say it imperils work on cancer and other illnesses.

The National Institutes of Health plans to severely cut the percentage of its grant money that can be used for overhead costs rather than research.

This will kill science in the US. This is how China wins. Why is this not on the news? Why are people not more upset about this? grants.nih.gov/grants/guide...

This!

Thank you #AACR for your strong support of #cancer researchers and the people who do that work! www.aacr.org/about-the-aa...

It's time to tackle rare cancers together - both a scientific opportunity and a moral imperative! I've shared a few brief thoughts in the Trends in Cancer opinions perspective on this topic - out now online www.cell.com/trends/cance...

So, we teamed up with Anne and Paul’s lab, along with Calvin Jan at Calico, with the aim of building an accessible & unbiased high-content cell profiling platform that could be applied to genome-scale CRISPR screens (Project PERISCOPE).

We’re big fans of using expression-based profiling (specifically Perturb-seq) to generate high-dimensional phenotypic profiles of perturbed cells, and w/ @oana-ursu.bsky.social & @boehmjesse.bsky.social have used it successfully for generating variant effect maps (www.nature.com/articles/s41...)

Our paper “A genome-wide atlas of human cell morphology” is finally out today in @naturemethods.bsky.social ! www.nature.com/articles/s41... (I tweeted about our preprint in 2023 over at the bad place, but deactivated my account, so here we go again!)

Yes. Exactly. One of (if not THE) best ROI for any govt spending.

Here's our latest, led by Drs. Riaz Gillani & Ryan Collins - we studied a type of inherited genetic event (structural variants) + risk of developing certain cancers in kids: @danafarber.bsky.social @bostonchildrens.bsky.social @broadinstitute.org @science.org www.science.org/doi/10.1126/...

Thrilled to share the results in Cancer Cell of years of hard work to develop classifiers for all major TCGA cancer subtypes, enabling assessment of differential drug response among cancer subtypes in clinical trials. www.cell.com/cancer-cell/...

Looking forward to delivering keynote address at the #slas2025 meeting January 25 - 29, 2025 (San Diego, CA, USA). I will share thoughts on current and future state of precision functional genomics to drive precision medicine forward. San Diego sunshine guaranteed! www.slas.org/publications...